Literature DB >> 18545898

When should "chronic migraine" patients be considered "refractory" to pharmacological prophylaxis?

Domenico D'Amico1, Massimo Leone, Licia Grazzi, Gennaro Bussone.   

Abstract

Patients with chronic headache forms evolving from a previous episodic migraine ('chronic migraine') are often difficult to treat. In this paper we focus attention on aspects we believe important for producing a definition of "refractory" in relation to this headache form. We propose a "chronic migraine" patient should be considered "refractory" to pharmacological prophylaxis when adequate trials of preventive therapies at adequate doses have failed to reduce headache frequency and improve headache-related disability and, in patients with medication overuse, reduce the consumption of symptomatic drugs. However before a definition of "refractory" chronic migraine can become established, generally accepted diagnostic criteria and treatment guidelines for this condition need to be developed.

Entities:  

Mesh:

Year:  2008        PMID: 18545898     DOI: 10.1007/s10072-008-0888-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  37 in total

1.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

Review 2.  Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach.

Authors:  Abouch Valenty Krymchantowski; Marcelo Eduardo Bigal
Journal:  Expert Rev Neurother       Date:  2006-03       Impact factor: 4.618

Review 3.  Risk factors for headache chronification.

Authors:  Ann I Scher; Lynn A Midgette; Richard B Lipton
Journal:  Headache       Date:  2008-01       Impact factor: 5.887

4.  Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen D Silberstein; Richard B Lipton; David W Dodick; Frederick G Freitag; Nabih Ramadan; Ninan Mathew; Jan L Brandes; Marcelo Bigal; Joel Saper; Steven Ascher; Donna M Jordan; Steven J Greenberg; Joseph Hulihan
Journal:  Headache       Date:  2007-02       Impact factor: 5.887

Review 5.  Comorbidity of migraine.

Authors:  Ann I Scher; Marcelo E Bigal; Richard B Lipton
Journal:  Curr Opin Neurol       Date:  2005-06       Impact factor: 5.710

6.  Topiramate in the treatment of chronic migraine.

Authors:  M Silvestrini; M Bartolini; M Coccia; R Baruffaldi; R Taffi; L Provinciali
Journal:  Cephalalgia       Date:  2003-10       Impact factor: 6.292

7.  Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.

Authors:  Joel R Saper; Alvin E Lake; Deborah T Cantrell; Paul K Winner; Jeffery R White
Journal:  Headache       Date:  2002-06       Impact factor: 5.887

Review 8.  Medication-overuse headache: a worldwide problem.

Authors:  Hans-Christoph Diener; Volker Limmroth
Journal:  Lancet Neurol       Date:  2004-08       Impact factor: 44.182

9.  Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes.

Authors:  M E Bigal; A M Rapoport; F D Sheftell; S J Tepper; R B Lipton
Journal:  Cephalalgia       Date:  2004-06       Impact factor: 6.292

10.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

View more
  12 in total

Review 1.  Peripheral neuromodulation in chronic migraine.

Authors:  F Perini; A De Boni
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

2.  Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial.

Authors:  Paola Di Fiore; Gennaro Bussone; Alberto Galli; Henri Didier; Cesare Peccarisi; Domenico D'Amico; Fabio Frediani
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

Review 3.  Treatment of the Patient with Refractory Headache.

Authors:  Alessandro S Zagami
Journal:  Curr Pain Headache Rep       Date:  2018-03-19

4.  Refractory migraine: the role of the physician in assessment and treatment of a problematic disease.

Authors:  Bruno Colombo; Dacia Dalla Libera; Gloria Dalla Costa; Giancarlo Comi
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307

5.  Vagus nerve stimulation in drug-resistant daily chronic migraine with depression: preliminary data.

Authors:  Alberto Proietti Cecchini; Eliana Mea; Vincenzo Tullo; Marcella Curone; Angelo Franzini; Giovanni Broggi; Mario Savino; Gennaro Bussone; Massimo Leone
Journal:  Neurol Sci       Date:  2009-05       Impact factor: 3.307

6.  Refractory migraine in a headache clinic population.

Authors:  Pablo Irimia; Jose-Alberto Palma; Roberto Fernandez-Torron; Eduardo Martinez-Vila
Journal:  BMC Neurol       Date:  2011-08-01       Impact factor: 2.474

7.  Prophylaxis of migraine: general principles and patient acceptance.

Authors:  Domenico D'Amico; Stewart J Tepper
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

8.  Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation.

Authors:  Paolo Martelletti; Zaza Katsarava; Christian Lampl; Delphine Magis; Lars Bendtsen; Andrea Negro; Michael Bjørn Russell; Dimos-Dimitrios D Mitsikostas; Rigmor Højland Jensen
Journal:  J Headache Pain       Date:  2014-08-28       Impact factor: 7.277

9.  A comparison of outcome of medical and surgical treatment of migraine headache: In 1 year follow-up.

Authors:  Mahmood Omranifard; Hossein Abdali; Mehdi Rasti Ardakani; Mohsen Talebianfar
Journal:  Adv Biomed Res       Date:  2016-07-29

10.  European headache federation consensus on the definition of resistant and refractory migraine : Developed with the endorsement of the European Migraine & Headache Alliance (EMHA).

Authors:  Simona Sacco; Mark Braschinsky; Anne Ducros; Christian Lampl; Patrick Little; Antoinette Maassen van den Brink; Patricia Pozo-Rosich; Uwe Reuter; Elena Ruiz de la Torre; Margarita Sanchez Del Rio; Alexandra J Sinclair; Zaza Katsarava; Paolo Martelletti
Journal:  J Headache Pain       Date:  2020-06-16       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.